Biodesix completes enrollment of VeriStrat clinical utility study

Biodesix announced that the observational registry study INSIGHT – Clinical Effectiveness Assessment of VeriStrat Testing and Validation of Immunotherapy Tests in NSCLC Subjects – has completed enrollment of 5,000 patients with non-small cell lung cancer – NSCLC -. The study was designed to further validate the utility of the VeriStrat test, a predictive and prognostic blood-based host immune classifier, and its ability to support treatment decisions for patients with NSCLC across different therapeutic approaches. Results from prior analyses of the INSIGHT study demonstrated that the VeriStrat test stratifies immune checkpoint inhibition treatment response in patients with advanced NSCLC. This data demonstrated that those classified as Host Immune Classifier Cold, also known as VeriStrat Poor, had superior median overall survival when receiving ICI plus chemotherapy versus ICI alone, independent of PD-L1 status. Future analyses of the INSIGHT study are planned in 2024, as monitoring of patient outcomes continues.